Evaluating 2B3, a novel immunotherapy in PDAPP model of amyloid pathology

Evans, Charles 2016. Evaluating 2B3, a novel immunotherapy in PDAPP model of amyloid pathology. PhD Thesis, Cardiff University. Item availability restricted.

Preview	PDF - Accepted Post-Print Version Download (3MB) | Preview
	PDF - Supplemental Material Restricted to Repository staff only Download (248kB)

Abstract

There are currently no disease-modifying therapies to halt or prevent the onset of Alzheimer’s disease (AD). Immunotherapy and antibodies targeting the neurotoxic amyloid-β (Aβ) peptide for its removal from the brain have provided a promising opportunity to provide disease-modifying therapies. However, despite promising pre-clinical data, any benefits have failed to translate to the clinic. This thesis evaluated an antibody approach that, rather than targeting amyloid per se, binds to the amyloid precursor protein (APP) at the β-secretase cleavage site to reduce amyloid production by steric hindrance (Thomas et al. 2011, 2013). The main hypothesis of this thesis was that 2B3 administration to aged PDAPP mice (Games et al. 1995), which overexpress a mutated form of APP (Indiana mutation; V717F), would (1) reduce APP metabolism and (2) Aβ production and (3) alleviate age-associated cognitive deficits in PDAPP mice.

Item Type:	Thesis (PhD)
Date Type:	Publication
Status:	Unpublished
Schools:	Pharmacy Psychology
Subjects:	B Philosophy. Psychology. Religion > BF Psychology
Date of First Compliant Deposit:	7 November 2016
Date of Acceptance:	4 November 2016
Last Modified:	06 Jan 2023 02:08
URI:	https://orca.cardiff.ac.uk/id/eprint/95846

Actions (repository staff only)

Edit Item